Sean Murphy, PhD
The goal is to devise interventions to improve outcome following acute brain injury by identifying potential candidates in experimental stroke models from those drugs either already in use or in human trials for other purposes. Part of the rationale is that this should hasten candidate drugs into the clinic. The focus is currently on progesterone and its metabolites, and on histone deacetylase inhibitors. These drugs that are not only protective of existing neurons but also activate endogenous repair processes, including neurogenesis.